Dr. Gordon, Chun-Kau CHAN
Speaker
Qualifications
Associate Consultant,
Department of Medicine & Therapeutics,
Prince of Wales Hospital,
Hong Kong SAR
Speaker Biography
Dr. Gordon CHAN graduated from the Chinese University of Hong Kong in 2011. He underwent training in internal medicine and nephrology, subsequently obtaining his specialist qualification in 2018. In 2024, he received the degree of Doctor of Medicine from the Chinese University of Hong Kong
Dr. CHAN is currently the Associate Consultant of the Department of Medicine & Therapeutics at Prince of Wales Hospital and an Honorary Clinical Assistant Professor at the Faculty of Medicine, the Chinese University of Hong Kong. In addition, he serves as the Honorary Treasurer of the Hong Kong Society of Transplantation, a Scientific Committee member of the Hong Kong Society of Nephrology, and a Task Force member (Asian Registry and Finance & Membership) of the Asian Society of Transplantation.
He has published numerous peer-reviewed research articles, focusing particularly on metabolic syndrome, including diabetes mellitus and obesity in patients with chronic kidney disease (CKD) and those undergoing peritoneal dialysis (PD).
Dr. CHAN is currently the Associate Consultant of the Department of Medicine & Therapeutics at Prince of Wales Hospital and an Honorary Clinical Assistant Professor at the Faculty of Medicine, the Chinese University of Hong Kong. In addition, he serves as the Honorary Treasurer of the Hong Kong Society of Transplantation, a Scientific Committee member of the Hong Kong Society of Nephrology, and a Task Force member (Asian Registry and Finance & Membership) of the Asian Society of Transplantation.
He has published numerous peer-reviewed research articles, focusing particularly on metabolic syndrome, including diabetes mellitus and obesity in patients with chronic kidney disease (CKD) and those undergoing peritoneal dialysis (PD).
Elderly Care in CKD: Expanding the Range of Kidney Protection with Advanced Treatment Strategies
Abstract:
Chronic kidney disease (CKD) in older adults is a worldwide epidemic that affects nearly 40% of people aged 65 or older. At present, there are no specific guidelines and recommendations regarding early identification and management of elderly with CKD. Unlike younger patients, CKD in elderly patients may be accompanied by geriatric syndromes, which include conditions commonly associated with aging, such as frailty, falls, malnutrition, and dementia. Therefore, management of CKD in the elderly requires not only standard strategies but also strategies that consider the unique characteristics of elderly patients. Sodium glucose co-transporter 2 (SGLT2) inhibitors are designed as oral anti-hyperglycemic agents by promoting renal excretion of glucose. Apart from their glucose-lowering effects, CV outcome trials have shown that they also provided cardiorenal benefits in patients with T2DM. Since then, more recent evidence has extended the use of SGLT2 inhibitors for the treatment of disease with high unmet needs, such as CKD, providing substantial cardiovascular benefits in a broad range of patients, including those without type 2 diabetes.In this lecture, the latest clinical evidence, recent international guideline recommendations and practical considerations on the use of SGLT2 inhibitors in the elderly population will be discussed.
Chronic kidney disease (CKD) in older adults is a worldwide epidemic that affects nearly 40% of people aged 65 or older. At present, there are no specific guidelines and recommendations regarding early identification and management of elderly with CKD. Unlike younger patients, CKD in elderly patients may be accompanied by geriatric syndromes, which include conditions commonly associated with aging, such as frailty, falls, malnutrition, and dementia. Therefore, management of CKD in the elderly requires not only standard strategies but also strategies that consider the unique characteristics of elderly patients. Sodium glucose co-transporter 2 (SGLT2) inhibitors are designed as oral anti-hyperglycemic agents by promoting renal excretion of glucose. Apart from their glucose-lowering effects, CV outcome trials have shown that they also provided cardiorenal benefits in patients with T2DM. Since then, more recent evidence has extended the use of SGLT2 inhibitors for the treatment of disease with high unmet needs, such as CKD, providing substantial cardiovascular benefits in a broad range of patients, including those without type 2 diabetes.In this lecture, the latest clinical evidence, recent international guideline recommendations and practical considerations on the use of SGLT2 inhibitors in the elderly population will be discussed.